HIV/AIDS
Studies from Kaiser Permanente in the area of HIV/AIDS described
Published in AIDS Weekly, April 6th, 2009
According to recent research from the United States, "Evaluate responses and safety of ritonavir-boosted atazanavir (''boosted atazanavir'') compared to unboosted atazanavir among antiretroviral-naive patients in the clinical managed care setting. Observational cohort analysis of atazanavir use (comparing ritonavir-boosted to non-boosted) at Kaiser Permanente and Group Health Cooperative from 2003 to 2006."
"Antiretroviral-naive patients initiating atazanavir were followed through 52 weeks of treatment. 443 patients were prescribed atazanavir (69 non-boosted; 15.5%). Boosted and non-boosted atazanavir groups were similar with respect to gender and age. Boosted...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-04-06)
More Articles from AIDS Weekly
- Albert Einstein College of Medicine
Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time - Antiretrovirals
Research reports on antiretrovirals from A. Kiboneka and colleagues provide new insights - Biotechnology Business
New biotechnology business findings from T.J. Wilkin and co-authors described - HIV/AIDS
Findings from A. Streinucercel et al in HIV/AIDS reported - HIV/AIDS
New findings from Vall d'Hebron University describe advances in HIV/AIDS - HIV/AIDS
New HIV/AIDS findings from University of Richmond described - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
